196 related articles for article (PubMed ID: 37526323)
1. A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 Sublineages.
Zhang X; Wu S; Liu J; Chen R; Zhang Y; Lin Y; Xi Z; Deng J; Pu Z; Liang C; Feng J; Li R; Lin K; Zhou M; Liu Y; Zhang X; Liu B; Zhang Y; He X; Zhang H
Adv Sci (Weinh); 2023 Sep; 10(27):e2301034. PubMed ID: 37526323
[TBL] [Abstract][Full Text] [Related]
2. A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates.
Liu Z; Zhou J; Wang X; Xu W; Teng Z; Chen H; Chen M; Zhang G; Wang Y; Huang J; Wang Q; Jiang S; Lu L
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2221713120. PubMed ID: 36897979
[TBL] [Abstract][Full Text] [Related]
3. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
[TBL] [Abstract][Full Text] [Related]
4. Mucosal SARS-CoV-2 Nanoparticle Vaccine Based on Mucosal Adjuvants and Its Immune Effectiveness by Intranasal Administration.
Xiao L; Yu W; Shen L; Yan W; Qi J; Hu T
ACS Appl Mater Interfaces; 2023 Aug; 15(30):35895-35905. PubMed ID: 37466148
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.
Fan C; Cohen AA; Park M; Hung AF; Keeffe JR; Gnanapragasam PNP; Lee YE; Gao H; Kakutani LM; Wu Z; Kleanthous H; Malecek KE; Williams JC; Bjorkman PJ
Immunity; 2022 Dec; 55(12):2419-2435.e10. PubMed ID: 36370711
[TBL] [Abstract][Full Text] [Related]
6. A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection.
Olivera-Ugarte SM; Bolduc M; Laliberté-Gagné MÈ; Blanchette LJ; Garneau C; Fillion M; Savard P; Dubuc I; Flamand L; Farnòs O; Xu X; Kamen A; Gilbert M; Rabezanahary H; Scarrone M; Couture C; Baz M; Leclerc D
Nanomedicine; 2022 Aug; 44():102584. PubMed ID: 35850421
[TBL] [Abstract][Full Text] [Related]
7. An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response.
Chen L; Zhang H; Li M; Wu B; Zhang Z; Gong R
Front Immunol; 2022; 13():1005321. PubMed ID: 36466882
[TBL] [Abstract][Full Text] [Related]
8. An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters.
Tabynov K; Solomadin M; Turebekov N; Babayeva M; Fomin G; Yadagiri G; Renu S; Yerubayev T; Petrovsky N; Renukaradhya GJ; Tabynov K
Sci Rep; 2023 Jul; 13(1):12115. PubMed ID: 37495639
[TBL] [Abstract][Full Text] [Related]
9. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.
Walls AC; Miranda MC; Pham MN; Schäfer A; Greaney A; Arunachalam PS; Navarro MJ; Tortorici MA; Rogers K; O'Connor MA; Shireff L; Ferrell DE; Brunette N; Kepl E; Bowen J; Zepeda SK; Starr T; Hsieh CL; Fiala B; Wrenn S; Pettie D; Sydeman C; Johnson M; Blackstone A; Ravichandran R; Ogohara C; Carter L; Tilles SW; Rappuoli R; O'Hagan DT; Van Der Most R; Van Voorhis WC; McLellan JS; Kleanthous H; Sheahan TP; Fuller DH; Villinger F; Bloom J; Pulendran B; Baric R; King N; Veesler D
bioRxiv; 2021 Mar; ():. PubMed ID: 33758839
[TBL] [Abstract][Full Text] [Related]
10. Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.
Ganesan S; Acosta H; Brigolin C; Orange K; Trabbic K; Chen C; Lien CE; Lin YJ; Lin MY; Chuang YS; Fattom A; Bitko V
PLoS One; 2022; 17(11):e0272594. PubMed ID: 36322572
[TBL] [Abstract][Full Text] [Related]
11. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
Konrath KM; Liaw K; Wu Y; Zhu X; Walker SN; Xu Z; Schultheis K; Chokkalingam N; Chawla H; Du J; Tursi NJ; Moore A; Adolf-Bryfogle J; Purwar M; Reuschel EL; Frase D; Sullivan M; Fry B; Maricic I; Andrade VM; Iffland C; Crispin M; Broderick KE; Humeau LMPF; Patel A; Smith TRF; Pallesen J; Weiner DB; Kulp DW
Cell Rep; 2022 Feb; 38(5):110318. PubMed ID: 35090597
[TBL] [Abstract][Full Text] [Related]
12. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.
Arunachalam PS; Walls AC; Golden N; Atyeo C; Fischinger S; Li C; Aye P; Navarro MJ; Lai L; Edara VV; Röltgen K; Rogers K; Shirreff L; Ferrell DE; Wrenn S; Pettie D; Kraft JC; Miranda MC; Kepl E; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; White AG; Trisal M; Hsieh CL; Russell-Lodrigue K; Monjure C; Dufour J; Spencer S; Doyle-Meyers L; Bohm RP; Maness NJ; Roy C; Plante JA; Plante KS; Zhu A; Gorman MJ; Shin S; Shen X; Fontenot J; Gupta S; O'Hagan DT; Van Der Most R; Rappuoli R; Coffman RL; Novack D; McLellan JS; Subramaniam S; Montefiori D; Boyd SD; Flynn JL; Alter G; Villinger F; Kleanthous H; Rappaport J; Suthar MS; King NP; Veesler D; Pulendran B
Nature; 2021 Jun; 594(7862):253-258. PubMed ID: 33873199
[TBL] [Abstract][Full Text] [Related]
13. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs.
Liu Z; Zhou J; Xu W; Deng W; Wang Y; Wang M; Wang Q; Hsieh M; Dong J; Wang X; Huang W; Xing L; He M; Tao C; Xie Y; Zhang Y; Wang Y; Zhao J; Yuan Z; Qin C; Jiang S; Lu L
Cell Res; 2022 Mar; 32(3):269-287. PubMed ID: 35046518
[TBL] [Abstract][Full Text] [Related]
14. Mosaic RBD Nanoparticles Elicit Protective Immunity Against Multiple Human Coronaviruses in Animal Models.
Zhang Y; Sun J; Zheng J; Li S; Rao H; Dai J; Zhang Z; Wang Y; Liu D; Chen Z; Ran W; Zhu A; Li F; Yan Q; Wang Y; Yu K; Zhang S; Wang D; Tang Y; Liu B; Cheng L; Huo J; Perlman S; Zhao J; Zhao J
Adv Sci (Weinh); 2024 Mar; 11(9):e2303366. PubMed ID: 38105421
[TBL] [Abstract][Full Text] [Related]
15. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines.
Walls AC; Miranda MC; Schäfer A; Pham MN; Greaney A; Arunachalam PS; Navarro MJ; Tortorici MA; Rogers K; O'Connor MA; Shirreff L; Ferrell DE; Bowen J; Brunette N; Kepl E; Zepeda SK; Starr T; Hsieh CL; Fiala B; Wrenn S; Pettie D; Sydeman C; Sprouse KR; Johnson M; Blackstone A; Ravichandran R; Ogohara C; Carter L; Tilles SW; Rappuoli R; Leist SR; Martinez DR; Clark M; Tisch R; O'Hagan DT; Van Der Most R; Van Voorhis WC; Corti D; McLellan JS; Kleanthous H; Sheahan TP; Smith KD; Fuller DH; Villinger F; Bloom J; Pulendran B; Baric RS; King NP; Veesler D
Cell; 2021 Oct; 184(21):5432-5447.e16. PubMed ID: 34619077
[TBL] [Abstract][Full Text] [Related]
16. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
[TBL] [Abstract][Full Text] [Related]
17. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
[TBL] [Abstract][Full Text] [Related]
18. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.
Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA
Front Immunol; 2022; 13():858904. PubMed ID: 35592324
[TBL] [Abstract][Full Text] [Related]
19. A triple-RBD-based mucosal vaccine provides broad protection against SARS-CoV-2 variants of concern.
Yang J; Liu MQ; Liu L; Li X; Xu M; Lin H; Liu S; Hu Y; Li B; Liu B; Li M; Sun Y; Chen YQ; Shi ZL; Yan H
Cell Mol Immunol; 2022 Nov; 19(11):1279-1289. PubMed ID: 36220993
[TBL] [Abstract][Full Text] [Related]
20. Mucosal vaccine-induced cross-reactive CD8
Ying B; Darling TL; Desai P; Liang CY; Dmitriev IP; Soudani N; Bricker T; Kashentseva EA; Harastani H; Raju S; Liu M; Schmidt AG; Curiel DT; Boon ACM; Diamond MS
Nat Immunol; 2024 Mar; 25(3):537-551. PubMed ID: 38337035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
